• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

    13.71 +0.04 (+0.26%)
    Streaming Delayed Price Updated: 2:43 PM EST, Jan 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Dr. Reddy's Laboratories Ltd Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
    From Aurigene Oncology Limited
    Via Business Wire
    News headline image
    Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
    From Aurigene Oncology Limited
    Via Business Wire
    News headline image
    Dr. Reddy’s Reports Record Revenues in Q1, Signals Steady Execution Through Transition Year
    Via AB Newswire
    Topics Earnings
    News headline image
    Dr. Reddy’s Q1FY26 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
    Via AB Newswire
    Topics Death
    News headline image
    Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
    From Alvotech
    Via GlobeNewswire
    News headline image
    Dr. Reddy’s Q4 & Full Year FY25 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
    From Alvotech
    Via GlobeNewswire
    News headline image
    Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy’s Q3 & 9MFY25 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
    From Dr. Reddy's Laboratories, Inc.
    Via Business Wire
    News headline image
    Dr. Reddy’s Q2 & H1FY25 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
    From Dr. Reddy’s Laboratories Inc.
    Via Business Wire
    Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression
    Via AB Newswire
    News headline image
    Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
    From Aurigene Oncology Limited
    Via Business Wire
    News headline image
    Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy’s Q1FY25 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
    Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
    Via MarketBeat
    News headline image
    Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
    From Aurigene Pharmaceutical Services Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    News headline image
    Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
    From Dr. Reddy's Laboratories Ltd.
    Via Business Wire
    News headline image
    Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.